• This Project has received funding from the European Union´s Horizon 2020 research and innovation programme under grant agreement No 945118
RESILIENCE helps you survive cancer with a strong heart
Twitter Youtube Facebook Linkedin Instagram

Why Lymphoma

Lymphoma patients are treated with a very homogeneous combination chemotherapy that includes anthracyclines.

This is an ideal setting for a controlled trial in order to reduce the chances of confounders. NHL patients are especially vulnerable to anthracycline-induced cardiotoxicity. Mean age of NHL diagnosis is in the eight decade of life, a time where cardiovascular comorbidities are frequent, increasing the likelihood of post-therapy heart failure. Another important rationale for choosing this cancer type as a target of this project is that there is a balance in the incidence of NHL diagnoses across genders (60% male/40%female). There is no conclusive information about gender differences in cancer therapy-induced cardiotoxicity. One main reason for this lack of information is that most of the studies evaluating the incidence of cardiotoxicity have been done in breast cancer patients, a malignancy with a very low representation of male patients. Our aim is to extend the results of the project beyond NHL to all cancer patients treated with anthracyclines

Resilience

Cardiac Magnetic Resonance

  • Cardiac magnetic resonance (CMR) it is a technique without radiation, which is considered the gold-standard for the evaluation of cardiac anatomy, function and even tissue composition.

Clinical Trial Synopsis

  • Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic PreConditioning.

For patients

Legals

Follow Us

Twitter Youtube Facebook Linkedin Instagram
  • This Project has received funding from the European Union´s Horizon 2020 research and innovation programme under grant agreement No 945118

RESILIENCE is a CNIC project with a multidisciplinary consortium | All Rights Reserved 2022

Logotipo Resilience

Are you a patient participating in RESILIENCE? Here you will find useful information about the details of your participation, activities specifically designed for you. You will also be able to contact RESILIENCE researchers.

In accordance with the provisions of Regulation (EU) 2016/679 on the protection of personal data of natural persons (GDPR), the personal information you have provided will be incorporated into the data processing systems of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) for the purpose of attending your registration application in the restricted area for patients participating in the RESILIENCE study. The legal basis for processing your personal data for this purpose is your explicit consent. Your personal data will not be disclosed to any recipients other than those to whom you authorise or when required by law to do so. You may exercise your rights of access, right to rectification, to object, to erasure, to restriction of processing, data portability and not to be subject to automated individual decision-making. To exercise these rights, as well as to obtain additional information about the processing of your personal data, you can consult the following link Terms and Conditions